The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma.
Joseph J Sacco
No relevant relationships to disclose
Paul D. Nathan
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Sarah Danson
No relevant relationships to disclose
Paul Lorigan
No relevant relationships to disclose
Steve Nicholson
No relevant relationships to disclose
Christian Ottensmeier
No relevant relationships to disclose
Philippa Corrie
No relevant relationships to disclose
Neil Steven
No relevant relationships to disclose
Andrew Goodman
No relevant relationships to disclose
James M. G. Larkin
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
T. R. Jeffry Evans
No relevant relationships to disclose
Satish Kumar
No relevant relationships to disclose
Sarah E Coupland
No relevant relationships to disclose
Paul Silcocks
No relevant relationships to disclose
Ernie Marshall
No relevant relationships to disclose